T. N. Rozhdestvenskaya

T. N. Rozhdestvenskaya

Auto-generated profile, based on publicly available information

T. N. Rozhdestvenskaya

Scientific-production enterprise «AVIVAC» ; Federal Scientific Centre VIEV

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2022 in Agrarian science
Verified
Journal Article
Open access
PDF file
TRT. N. Rozhdestvenskaya
T. N. Rozhdestvenskaya
LKL. Karimova
L. Karimova
SPS. V. Pankratov
S. V. Pankratov
ARA. V. Ruzina
A. V. Ruzina
ETE. V. Tomina
E. V. Tomina
Introduction. Chicken cholera is one of the most dangerous avian infectious diseases, causing significant economic damage to the industrial poultry production. Chicken cholera usually occurs in septic form, and causes high morbidity and mortality (60–80%), but recently it has become chronic, subclinical and associated. Inactivated emulsion vaccines are used worldwide to prevent chicken cholera and provide high and long-term immunity. However, there is a problem with residual reactogenicity of inactivated vaccines, particularly of the bacterial variants. This problem can be solved by using safer, next-generation adjuvants. The aim of the article is to study the physical and biological properties and determine the optimal inoculation volume and method of administration of inactivated vaccines against chicken cholera , based on different adjuvants.Materials and methods. Formaldehyde inactivated culture of P. multocida st. 115and a number of adjuvants (“Montanide GEL-02” and oil adjuvants “Montanide ISA 70 VG” and “Montanide ISA 78 VG”) were used for vaccine production. The vaccine samples were tested for sterility, stability and viscosity by conventional methods. Determination of reactogenicity and antigenic activity of the vaccines was carried out on young 30-days old chickensof egg-laying type.Results. The vaccine sample based on the adjuvant “Montanide ISA 70 VG” containing 1.5 billion P. Multocida microbial cells in a single immunizing dose of 0.3 cm3 was found to be the best among the tested preparations. When assessing the reactogenicity, it was obvious that all samples, regardless of the type of adjuvant, showed more pronounced residual reactogenic properties when injected intramuscularly into the chest muscle than when injected subcutaneously into the middle third of the neck.

25 April 2025 in Agrarian science
Verified
Journal Article
Open access
PDF file
AFA. V. Frolov
A. V. Frolov
ARA. V. Ruzina
A. V. Ruzina
NVN. V. Vasyukov
N. V. Vasyukov
TRT. N. Rozhdestvenskaya
T. N. Rozhdestvenskaya
Relevance. The basis of protection against clinical expression of avian influenza subtype H9 (hereafter referred to as H9) is the level of immunity to this infection. The consequences of post-infection immunity do not exclude a decrease in production performance. It is therefore a priority to ensure post-vaccination immunity in birds. In the pathology of birds, the relationship between the epizootic situation of Newcastle disease (hereinafter — ND) and AI (H9) is important. Significant differences in the development of post-vaccination immunity against AI (H9) in replacement chickens may be due to the vaccines used in farms.The aim of the work is to compare the effectiveness of both monovaccines against HP (H9) and bivalent vaccines against this infection and NB, taking into account the differences in adjuvants in these drugs.Methods. Four experimental (20 heads each) and one control (10 heads each) group of chickens were formed for research. The experiment used birds that are not immune to HP (H9). In the experimental groups, chickens were vaccinated with inactivated vaccines at the age of 30 days. followed by their revaccination with a monthly interval. Blood serum sampling was performed every two weeks from the moment of initial immunization of chickens. The assessment of the level of immunity tension against GP (H9) and NB was carried out when RTGA was administered with specific antigens.Results. The dependence of the intensity and level of post-vaccination immunity on the difference in valence of the vaccines and adjuvants used was established. The use of monovaccines against AI (H9) did not provide a fundamental advantage over the use of bivalent vaccines against AI (H9) and ND, taking into account the adjuvants used.